In a nutshell This article reviewed new treatment options for patients with relapsed Hodgkin’s lymphoma (HL). Some background The most common front-line (primary) chemotherapy regimen for the treatment of HL is ABVD (doxorubicin, bleomycin, vinblastine, dacarbazine). 88 – 94% of patients with HL respond to this treatment. However, 10...
Read More
In a nutshell This study investigated the effectiveness of autologous stem cell transplantation (autoSCT) for patients with follicular lymphoma who experienced early treatment failure (ETF; relapse or disease progression within 2 years after first-line therapy). This study concluded that autoSCT may be an effective option for these patients. Some...
Read More
In a nutshell This study evaluated the effectiveness and safety of duvelisib in patients with chronic lymphocytic leukemia (CLL). This study concluded that duvelisib may be an effective new therapy with manageable side effects. Some background CLL is the most common type of leukemia in adults in the U.S. Although therapy options have increased, many...
Read More
In a nutshell This study evaluated the safety and effectiveness of venetoclax (Venclexta) plus BR (bendamustine, rituximab) in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma (NHL). This study concluded that this treatment was tolerated and showed promising effectiveness in these patients. Some...
Read More
In a nutshell This study investigated the cardiovascular (heart and blood vessels) safety of carfilzomib (Kyprolis) in patients with relapsed or refractory (does not respond to treatment) multiple myeloma. This study concluded that the benefits of carfilzomib outweighed its risks. Some background Multiple myeloma is a type of cancer of the bone...
Read More
In a nutshell This article reviewed the treatment options for patients with very high-risk Hodgkin’s lymphoma (HL). Some background Although aggressive lymphomas are sensitive to chemotherapy, many patients do not respond well to first-line treatment. Many patients with Hodgkin’s lymphoma may develop disease progression or relapse after...
Read More
In a nutshell This study reviewed current and new targeted therapies for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. Some background Ibrutinib (Imbruvica) remains the current standard of care for patients with mantle cell lymphoma (MCL) who relapse or develop refractory disease after initial...
Read More
In a nutshell This study investigated the safety and effectiveness of coltuximab ravtansine for relapsed or refractory (does not respond to treatment) diffuse large B-cell lymphoma. The authors concluded that coltuximab ravtansine monotherapy was reasonably effective and well-tolerated in these patients. Some background The most widely used treatment...
Read MoreIn a nutshell This study investigated the safety and effectiveness of ibrutinib (Imbruvica) for patients with relapsed or refractory (does not respond to treatment) mantle cell lymphoma. This study concluded that ibrutinib is effective and well tolerated in everyday clinical practice. Some background Mantle cell lymphoma (MCL) is a rare but aggressive...
Read More
In a nutshell This study investigated the safety and effectiveness of MOR208 in patients with relapsed or refractory (does not respond to treatment) non-Hodgkin’s lymphoma. This study concluded that MOR208 monotherapy was safe and showed promising results in these patients. Some background Chemoimmunotherapy is the current standard first-line...
Read MoreIn a nutshell This study investigated the long-term safety and effectiveness of ibrutinib (Imbruvica) plus rituximab (Rituxan) for relapsed or refractory (does not respond to treatment) mantle cell lymphoma. This study concluded that this treatment is safe and effective for relapsed or refractory mantle cell lymphoma. Some background Mantle cell...
Read More
In a nutshell This study investigated the safety and effectiveness of alloHCT (allogeneic hematopoietic stem cell transplantation) in patients with chronic lymphocytic leukemia (CLL) pre-treated with ibrutinib (Imbruvica). This study concluded that ibrutinib does not affect the safety of alloHCT. Some background Ibrutinib has become the standard of...
Read More
